Practical challenges and considerations in adopting biosimilars in oncology clinical practice within a large healthcare system
Expert Review of Clinical Pharmacology · 2025
DOI: 10.1080/17512433.2025.2492063 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2025. Verfasst von Mansoor A Khan und 18 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Care Department, King Abdulaziz Medical City, Jeddah, Saudi Arabia. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
INTRODUCTION: Biosimilars have the potential to offer cost savings with comparable efficacy and safety to innovator products and, thus, increase access to treatment for more patients. However, there were significant challenges in the acceptance of oncology biosimilars in our organization in the beginning which we addressed by implementing practical strategies described in the paper. AREAS COVERED: While much of the published literature places an emphasis on the pharmacoeconomic impact of biosimilars, this paper is a novel addition to the literature because it provides practical experience and detailed processes for the formulary adoption and implementation of oncology biosimilars along with a focus on their pharmacoeconomic impact, education of oncology healthcare professionals, pharmacovigilance, and integration into the electronic health record. A narrative literature review was conducted to identify the existing evidence on biosimilar adoption and implementation in the oncology setting. EXPERT OPINION: Healthcare organizations must establish a consistent method for assessing and adopting oncology biosimilars to increase efficiency and coordination among the many team members responsible for their introduction into clinical practice. Conducting medication use evaluations and real-world evidence studies of biosimilars can help in building trust among healthcare professionals and patients in biosimilars.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Care Department, King Abdulaziz Medical City, Jeddah, Saudi Arabia.
- King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
- King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
- Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
- King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
- College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
ORCID-Profile: Mansoor A Khan, Consuela Cheriece Yousef
Zitieren
APA
Khan, M. A., Abu Esba, L. C., Yousef, C. C., Alharbi, M., Modaimegh, H., Metwali, H., Abdulkarim, H., Alshamrani, M., Aseeri, M., Almansour, M., Alsaeed, A., Alahmari, M., Ansari, A. N., Alfoheidi, M., Absi, A., Alfayea, T., Youssif, E., Alhejazi, A., & Alodhaib, M. (2025). Practical challenges and considerations in adopting biosimilars in oncology clinical practice within a large healthcare system. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2025.2492063
Vancouver
Khan MA, Abu Esba LC, Yousef CC, Alharbi M, Modaimegh H, Metwali H, et al. Practical challenges and considerations in adopting biosimilars in oncology clinical practice within a large healthcare system. Expert Review of Clinical Pharmacology. 2025. doi:10.1080/17512433.2025.2492063
BibTeX
@article{Khan2025,
author = {Khan, Mansoor A and Abu Esba, Laila Carolina and Yousef, Consuela Cheriece and Alharbi, Mohammed and Modaimegh, Hind and Metwali, Hend and Abdulkarim, Hana and Alshamrani, Majed and Aseeri, Mohamad and Almansour, Mubarak and Alsaeed, Ahmad and Alahmari, Mousa and Ansari, Anjum Naeem and Alfoheidi, Meteb and Absi, Ahmed and Alfayea, Turki and Youssif, Eman and Alhejazi, Ayman and Alodhaib, Mansour},
title = {Practical challenges and considerations in adopting biosimilars in oncology clinical practice within a large healthcare system},
journal = {Expert Review of Clinical Pharmacology},
year = {2025},
doi = {10.1080/17512433.2025.2492063}
}
EUVIMED